OpenAI has bought Orchestra Bio, a company whose software helps drug developers keep a sprawling program on track, and will fold the team and technology into Rosalind, OpenAI’s life-sciences line of models and tools. OpenAI announced the deal on 20 October 2026 and did not disclose financial terms.
Orchestra’s platform lets scientists and program leaders hand off the routine following of studies and campaigns to AI agents. When something slips, such as a failed manufacturing batch that pushes back a clinical trial, the agents work out which activities and timelines are hit, collect the relevant information, and lay out options for a response.
Rosalind has so far covered the science. GPT-Rosalind helps researchers reason through biology and chemistry questions, and Rosalind Workbench links that ability to lab tools and data. Orchestra adds the project-management layer. OpenAI’s announcement names Novo Nordisk and Moderna as organizations it works with in the field.
The target is a slow process: OpenAI puts the road from target discovery to US approval at ten to fifteen years. The announcement offers goals, not customer results. For biotech software vendors selling coordination tools, a frontier lab now competes in their category.
Reported by OpenAI on 20 October 2026.
